According to Bohui Innovation's announcement, the company recently obtained a Class III “Medical Device Registration Certificate” issued by the State Drug Administration. The products are Mycobacterium tuberculosis complex and rifampicin and isoniazid resistance gene mutation detection kits. The registration certificate is valid from October 9, 2026 to October 8, 2031. Obtaining this registration certificate has enriched the company's product range, which is conducive to enhancing core competitiveness and market expansion capabilities. There is uncertainty about the actual sales situation of the products.
Zhitongcaijing · 2d ago
Share
Listen to the news
According to Bohui Innovation's announcement, the company recently obtained a Class III “Medical Device Registration Certificate” issued by the State Drug Administration. The products are Mycobacterium tuberculosis complex and rifampicin and isoniazid resistance gene mutation detection kits. The registration certificate is valid from October 9, 2026 to October 8, 2031. Obtaining this registration certificate has enriched the company's product range, which is conducive to enhancing core competitiveness and market expansion capabilities. There is uncertainty about the actual sales situation of the products.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending